<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306227</url>
  </required_header>
  <id_info>
    <org_study_id>PHRCIR07-DR-TOURNEUX</org_study_id>
    <nct_id>NCT01306227</nct_id>
  </id_info>
  <brief_title>L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia</brief_title>
  <official_title>L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Transient Hypothyroxinemia of Prematurity: a Prospective Randomized Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient hypothyroxinemia of prematurity (THOP) is associated with neurodevelopmental
      impairment in preterm newborns &lt; 32 weeks of gestation (WG). It is not known whether
      L-Thyroxine supplementation for preterm newborns &lt;32 WG with THOP is beneficial.

      The purpose of this study is to compare L-thyroxine treatment vs. placebo in newborn less
      than 32 WG with THOP.

      The primary endpoint is the neurodevelopmental outcome at two years of life, assessed by the
      Brunet-Lézine score. The secondary endpoints are: death, bronchopulmonary dysplasia (oxygen
      therapy at 28 days of life and at 36 weeks of postnatal age), patent ductus arteriosus, shock
      requiring fluid loading or vasoactive treatments, enterocolitis, intraventricular hemorrhage,
      retinopathy of prematurity, deafness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm newborns &lt;32 weeks of gestation (WG) are screened for THOP between day 5 and day 7 of
      life. THOP is defined by thyroid-stimulating hormone (TSH) &lt; 20 mIU/L and FT4 &lt; 0.80 ng/dL.
      After obtaining written consent from the parents, preterm newborns &lt;32 WG with THOP will be
      included. Randomization is stratified by center and 2 age-groups (24-28 WG and 29-32 WG). One
      arm will receive L-thyroxine treatment and the other arm will receive placebo. Treatment will
      be started within one week after diagnosis and will last 6 weeks. TSH and FT4 will be assayed
      2 weeks after stopping treatment.

      The primary endpoint is the neurodevelopmental outcome at two years of life, assessed by the
      Brunet-Lézine score.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurodevelopmental outcome</measure>
    <time_frame>2 years old</time_frame>
    <description>Brunet-Lézine score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity associated with management of newborns &lt; 32 WG with hypothyroxinemia</measure>
    <time_frame>discharge, 1 year, 2 years</time_frame>
    <description>Death
Bronchopulmonary dysplasia (oxygen therapy at 28 days of life and at 36 weeks of postnatal age)
Patent ductus arteriosus,
Shock requiring fluid loading or vasoactive treatments
Enterocolitis
Intraventricular hemorrhage
Retinopathy of prematurity
Deafness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypothyroxinemia</condition>
  <arm_group>
    <arm_group_label>water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment with water for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Thyroxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment with L-Thyroxine for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Thyroxine</intervention_name>
    <description>Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.</description>
    <arm_group_label>L-Thyroxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>water</intervention_name>
    <description>Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.</description>
    <arm_group_label>water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age &lt; 32 WG

          -  FT4 (5, 6 or 7 days of life) ≤ 0.8 ng/dL

          -  TSH (5, 6 or 7 days of life) &lt; 20 mIU/L

          -  Written consent from the parents

        Exclusion Criteria:

          -  Maternal thyroid disease

          -  FT4 (5, 6 or 7 days of life) &gt; 0.8 ng/dL

          -  TSH (5, 6 or 7 days of life) &gt; 20 mIU/L

          -  Grade III or IV intracerebral hemorrhage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Tourneux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amiens University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <state>Basse normandie</state>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lens Hospital</name>
      <address>
        <city>Lens</city>
        <state>Nord- Pas de calais</state>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infant, newborn</keyword>
  <keyword>Infant, preterm</keyword>
  <keyword>Thyroid</keyword>
  <keyword>Outcome</keyword>
  <keyword>Newborns less than 32 weeks of gestation</keyword>
  <keyword>TSH &lt; 20 mIU/L and a FT4 &lt; 0.80 ng/dL</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

